
Imara
Dedicated to developing novel therapeutics for people living with sickle cell disease and other hemoglobinopathies.
Market cap
$143m
Enterprise value
$55m
Share price
$48.01 IMRA
Authorizing premium user...
Dedicated to developing novel therapeutics for people living with sickle cell disease and other hemoglobinopathies.